2.4.1.150	diagnostics	GCNT2 is a regulator of epithelial-mesenchymal transition (EMT) and a candidate prognostic indicator of outcome in esophageal squamous cell carcinoma (ESCC) patients	759012	
2.4.1.150	diagnostics	GCNT3 might be an essential glycosylation-related molecule in colorectal cancer and epithelial ovarian cancer progression, with potential interest as a predictive biomarker of response to chemotherapy. GCNT3 high-expressing Stage III-IV EOC patients have better response to conventional treatment and clinical outcome. Clinical relevance of GCNT3 expression in epithelial ovarian cancer (EOC), role of GCNT3 as a biomarker for cancer patients, overview	760171	
2.4.1.150	medicine	GCNT2 is overexpressed in highly metastatic breast cancer and its expression correlates with adverse pathologic phenotypes. Blocking TGF-beta/GCNT2 signaling is a promising approach for targeting metastatic breast cancer	758992	
2.4.1.150	pharmacology	targeting mucin biosynthesis through GCNT3 may improve drug responsiveness	758993	
2.4.1.150	synthesis	cIGnT6 transfers multiple GlcNAc branches to long linear polylactosamines, a prerequisite for improving enzyme-assisted in vitro synthesis of a type of multivalent sialyl Lewis x glycans that are high affinity inhibitors of lymphocyte L-selectin, enzyme allows general polylactosamine synthesis	638565